Overview Dividends

(CPB) Campbell’s - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US1344291091

Soups, Sauces, Broths, Cookies, Crackers, Chips

Packaged Foods & Meats
Market Cap in USD: 8,428m

IPO / Inception: 1985-07-01
Return 12m vs S&P 500: -38.4%

EPS (Earnings per Share)

EPS CAGR: 2.97%
EPS Trend: 6.0%

Last SUE: 1.47
Qual. Beats: 3

Revenue

Rev. CAGR: 5.26%
Rev. Trend: 58.2%

Last SUE: 0.71
Qual. Beats: 0

Dividends

Dividend Yield	6.80%
Yield on Cost 5y	4.79%
Yield CAGR 5y	1.40%
Payout Consistency	70.8%
Payout Ratio	54.6%

Risk via 5d forecast
Volatility	23.1%
Value at Risk 5%th	37.4%
Relative Tail Risk	-1.73%

Reward TTM
Sharpe Ratio	-1.23
Alpha	-36.68
CAGR/Max DD	-0.39

Character TTM
Hurst Exponent	0.348
Beta	0.188
Beta Downside	0.110

Drawdowns 3y
Max DD	45.50%
Mean DD	22.44%
Median DD	21.83%

Description: CPB Campbell’s November 04, 2025

The Campbell’s Company (NYSE: CPB) manufactures and markets a broad portfolio of food and beverage brands across two segments-Meals & Beverages and Snacks-serving retail and food-service channels in the United States, Canada, and Latin America. The Meals & Beverages segment includes iconic items such as Campbell’s soups, Swanson broths, V8 juices, and Pacific Foods plant-based beverages, while the Snacks segment houses Pepperidge Farm cookies, Goldfish crackers, Kettle Brand chips, and Snyder’s pretzels, among others.

Key recent metrics: CPB reported FY 2023 net sales of roughly $5.7 billion, with the Snacks segment delivering a 4.5 % higher contribution margin than the Meals & Beverages segment, reflecting a strategic shift toward higher-margin, on-the-go products. Inflation-driven input-cost volatility and a consumer tilt toward healthier, plant-based options remain primary economic drivers for the business; CPB’s acquisition of Pacific Foods in 2020 positions it to capture growth in the “better-for-you” category, which the packaged-foods industry is seeing a 6-7 % CAGR in North America. Additionally, the company’s exposure to private-label competition in mass discounters adds execution risk to its pricing power.

If you want to explore CPB’s valuation sensitivities, cash-flow projections, and peer-group benchmarks in more depth, ValueRay’s analytics platform offers a convenient way to continue the research.

Piotroski VR‑10 (Strict, 0-10) 4.0

Net Income (578.0m TTM) > 0 and > 6% of Revenue (6% = 609.5m TTM)

FCFTA 0.05 (>2.0%) and ΔFCFTA -0.14pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue -5.58% (prev -3.32%; Δ -2.27pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.07 (>3.0%) and CFO 1.13b > Net Income 578.0m (YES >=105%, WARN >=100%)

Net Debt (6.80b) to EBITDA (1.53b) ratio: 4.44 <= 3.0 (WARN <= 3.5)

Current Ratio 0.82 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (299.0m) change vs 12m ago -0.66% (target <= -2.0% for YES)

Gross Margin 29.97% (prev 30.84%; Δ -0.87pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 64.93% (prev 61.38%; Δ 3.54pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 3.27 (EBITDA TTM 1.53b / Interest Expense TTM 339.0m) >= 6 (WARN >= 3)

Altman Z'' 1.70

(A) -0.04 = (Total Current Assets 2.56b - Total Current Liabilities 3.13b) / Total Assets 15.18b

(B) 0.31 = Retained Earnings (Balance) 4.77b / Total Assets 15.18b

(D) 0.42 = Book Value of Equity 4.75b / Total Liabilities 11.22b

Total Rating: 1.70 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 61.91

1. Piotroski 4.0pt

2. FCF Yield 4.51%

3. FCF Margin 6.76%

4. Debt/Equity 1.76

5. Debt/Ebitda 4.44

6. ROIC - WACC (= 3.56)%

7. RoE 14.78%

8. Rev. Trend 58.19%

9. EPS Trend 5.99%

What is the price of CPB shares?

As of December 20, 2025, the stock is trading at USD 28.58 with a total of 11,615,467 shares traded.
Over the past week, the price has changed by +0.91%, over one month by -7.54%, over three months by -13.48% and over the past year by -28.05%.

Is CPB a buy, sell or hold?

Campbell’s has received a consensus analysts rating of 3.13. Therefor, it is recommend to hold CPB.

Strong Buy: 4
Buy: 2
Hold: 12
Sell: 3
Strong Sell: 2

What are the forecasts/targets for the CPB price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	32.3	13.1%
Analysts Target Price	32.3	13.1%
ValueRay Target Price	28.3	-1%

CPB Fundamental Data Overview December 17, 2025

Market Cap USD = 8.43b (8.43b USD * 1.0 USD.USD)
P/E Trailing = 14.5722
P/E Forward = 11.6822
P/S = 0.8297
P/B = 2.1654
P/EG = 0.7124
Beta = -0.057
Revenue TTM = 10.16b USD
EBIT TTM = 1.11b USD
EBITDA TTM = 1.53b USD
Long Term Debt = 6.10b USD (from longTermDebt, last quarter)
Short Term Debt = 874.0m USD (from shortTermDebt, last quarter)
Debt = 6.97b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 6.80b USD (from netDebt column, last quarter)
Enterprise Value = 15.23b USD (8.43b + Debt 6.97b - CCE 168.0m)
Interest Coverage Ratio = 3.27 (Ebit TTM 1.11b / Interest Expense TTM 339.0m)
FCF Yield = 4.51% (FCF TTM 687.0m / Enterprise Value 15.23b)
FCF Margin = 6.76% (FCF TTM 687.0m / Revenue TTM 10.16b)
Net Margin = 5.69% (Net Income TTM 578.0m / Revenue TTM 10.16b)
Gross Margin = 29.97% ((Revenue TTM 10.16b - Cost of Revenue TTM 7.11b) / Revenue TTM)
Gross Margin QoQ = 29.59% (prev 30.37%)
Tobins Q-Ratio = 1.00 (Enterprise Value 15.23b / Total Assets 15.18b)
Interest Expense / Debt = 1.16% (Interest Expense 81.0m / Debt 6.97b)
Taxrate = 24.22% (62.0m / 256.0m)
NOPAT = 838.9m (EBIT 1.11b * (1 - 24.22%))
Current Ratio = 0.82 (Total Current Assets 2.56b / Total Current Liabilities 3.13b)
Debt / Equity = 1.76 (Debt 6.97b / totalStockholderEquity, last quarter 3.96b)
Debt / EBITDA = 4.44 (Net Debt 6.80b / EBITDA 1.53b)
Debt / FCF = 9.90 (Net Debt 6.80b / FCF TTM 687.0m)
Total Stockholder Equity = 3.91b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.81% (Net Income 578.0m / Total Assets 15.18b)
RoE = 14.78% (Net Income TTM 578.0m / Total Stockholder Equity 3.91b)
RoCE = 11.06% (EBIT 1.11b / Capital Employed (Equity 3.91b + L.T.Debt 6.10b))
RoIC = 7.63% (NOPAT 838.9m / Invested Capital 10.99b)
WACC = 4.07% (E(8.43b)/V(15.40b) * Re(6.71%) + D(6.97b)/V(15.40b) * Rd(1.16%) * (1-Tc(0.24)))
Discount Rate = 6.71% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 0.0 | Cagr: 0.0%
[DCF Debug] Terminal Value 77.36% ; FCFE base≈713.0m ; Y1≈670.6m ; Y5≈629.3m
Fair Price DCF = 37.79 (DCF Value 11.27b / Shares Outstanding 298.1m; 5y FCF grow -7.64% → 3.0% )
EPS Correlation: 5.99 | EPS CAGR: 2.97% | SUE: 1.47 | # QB: 3
Revenue Correlation: 58.19 | Revenue CAGR: 5.26% | SUE: 0.71 | # QB: 0
EPS next Quarter (2026-01-31): EPS=0.58 | Chg30d=-0.060 | Revisions Net=-3 | Analysts=15
EPS current Year (2026-07-31): EPS=2.44 | Chg30d=-0.024 | Revisions Net=-10 | Growth EPS=-18.0% | Growth Revenue=-3.3%
EPS next Year (2027-07-31): EPS=2.63 | Chg30d=-0.045 | Revisions Net=-11 | Growth EPS=+7.8% | Growth Revenue=+1.2%

Additional Sources for CPB Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle